Delving into the Latest Updates on Taizhou Qirui Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Tags

Respiratory Diseases

Neoplasms

Diagnostic radiopharmaceuticals

Peptide Conjugate Radionuclide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Diagnostic radiopharmaceuticals	1
Peptide Conjugate Radionuclide	1

Top 5 Target	Count

αvβ3(Integrin alpha-V/beta-3)	1

主要目的：与氟[18F]脱氧葡糖PET-CT相比，评价氟[18F]阿法肽PET-CT用于诊断非小细胞肺癌淋巴结转移的灵敏度与特异性。次要目的：与氟[18F]脱氧葡糖PET-CT相比，评价氟[18F]阿法肽PET-CT用于诊断非小细胞肺癌淋巴结转移的准确性、阳性预测值、阴性预测值；与氟[18F]脱氧葡糖PET-CT相比，评价氟[18F]阿法肽PET-CT在非小细胞肺癌的安全性特征。探索性目的：比较氟[18F]阿法肽PET-CT与氟[18F]脱氧葡糖PET-CT相比诊断非小细胞肺癌淋巴结转移的一致性；整合素αvβ3表达情况（可选）。

[Translation]

Primary objective: Compared with 18F-FDG PET-CT, evaluate the sensitivity and specificity of 18F-FDG PET-CT in diagnosing lymph node metastasis of non-small cell lung cancer. Secondary objective: Compared with 18F-FDG PET-CT, evaluate the accuracy, positive predictive value, and negative predictive value of 18F-FDG PET-CT in diagnosing lymph node metastasis of non-small cell lung cancer; Compared with 18F-FDG PET-CT, evaluate the safety characteristics of 18F-FDG PET-CT in non-small cell lung cancer. Exploratory objective: Compared with 18F-FDG PET-CT, compare the consistency of 18F-FDG PET-CT in diagnosing lymph node metastasis of non-small cell lung cancer; Expression of integrin αvβ3 (optional).

Start Date-

Sponsor / Collaborator

Taizhou Qirui Pharmaceutical Technology Co., Ltd.

[+1]

CTR20192146 / CompletedPhase 1

一项观察氟[18F]阿法肽注射液在中国健康成年受试者体内的安全性、药代动力学特征以及生物分布的临床研究

[Translation] A clinical study to observe the safety, pharmacokinetic characteristics and biodistribution of 18F-fluoro[18F]alfatide injection in healthy Chinese adult subjects

主要目的：观察氟[18F]阿法肽注射液在中国健康成年受试者中单次注射的安全性及耐受性。次要目的：评价氟[18F]阿法肽注射液在中国健康成年受试者中单次注射的药代动力学（PK）特征；评估氟[18F]阿法肽注射液在中国健康成年受试者体内放射性分布特征及辐射暴露量。

[Translation]

Primary objective: To observe the safety and tolerability of a single injection of fluoro[18F] alpha peptide injection in healthy Chinese adult subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of a single injection of fluoro[18F] alpha peptide injection in healthy Chinese adult subjects; To assess the radioactivity distribution characteristics and radiation exposure of fluoro[18F] alpha peptide injection in healthy Chinese adult subjects.

Start Date07 Nov 2019

Sponsor / Collaborator

Taizhou Qirui Pharmaceutical Technology Co., Ltd.

[+1]

100 Clinical Results associated with Taizhou Qirui Pharmaceutical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Taizhou Qirui Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Deals associated with Taizhou Qirui Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Taizhou Qirui Pharmaceutical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data